Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Zynerba Pharmaceuticals, Inc is a drug manufacturers-specialty & generic business based in the US. Zynerba Pharmaceuticals shares (ZYNE) are listed on the NASDAQ and all prices are listed in US Dollars. Zynerba Pharmaceuticals employs 28 staff and has a trailing 12-month revenue of around USD$86,000.
|52-week range||USD$2.55 - USD$9|
|50-day moving average||USD$4.3484|
|200-day moving average||USD$3.9025|
|Wall St. target price||USD$7.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.892|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-38.83%|
|Return on equity TTM||-69.15%|
|Market capitalisation||USD$139.8 million|
TTM: trailing 12 months
There are currently 4.1 million Zynerba Pharmaceuticals shares held short by investors – that's known as Zynerba Pharmaceuticals's "short interest". This figure is 0.8% down from 4.2 million last month.
There are a few different ways that this level of interest in shorting Zynerba Pharmaceuticals shares can be evaluated.
Zynerba Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Zynerba Pharmaceuticals shares currently shorted divided by the average quantity of Zynerba Pharmaceuticals shares traded daily (recently around 1.4 million). Zynerba Pharmaceuticals's SIR currently stands at 2.9. In other words for every 100,000 Zynerba Pharmaceuticals shares traded daily on the market, roughly 2900 shares are currently held short.
However Zynerba Pharmaceuticals's short interest can also be evaluated against the total number of Zynerba Pharmaceuticals shares, or, against the total number of tradable Zynerba Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zynerba Pharmaceuticals's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Zynerba Pharmaceuticals shares in existence, roughly 140 shares are currently held short) or 0.1581% of the tradable shares (for every 100,000 tradable Zynerba Pharmaceuticals shares, roughly 158 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zynerba Pharmaceuticals.
Find out more about how you can short Zynerba Pharmaceuticals stock.
We're not expecting Zynerba Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Zynerba Pharmaceuticals's shares have ranged in value from as little as $2.55 up to $9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zynerba Pharmaceuticals's is 2.7962. This would suggest that Zynerba Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder; is in Phase II clinical trial for treating pediatric behavioral and emotional symptoms of 22q11.2 deletion syndrome; and to treat children and adolescent patients with fragile X syndrome. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.